I-Mab Biopharma

I-Mab Biopharma 是一家在股票代码 IMAB (CN) 下上市的公司。

查看带有其 10 名主要高管的组织结构图

I-Mab Biopharma 搜索最多的简介

• Xi-Yong Fu, Chief Executive Officer
• Chia-Hung Yang, Independent Director
• Shuai Chen, Director

高管在I-Mab Biopharma变化

• Xi-Yong Fu 曾任 Interim Chief Executive Officer, 现升职为 Chief Executive Officer  (新闻发布的2024十一月8号).
• Wei Fu 曾任 Director, 现升职为 Chairman of the Board  (新闻发布的2024七月16号).

创建提醒
跟踪 I-Mab Biopharma 的高管变动

I-Mab Biopharma 拥有 1,834 家竞争者，其中包括 Pfizer (美国(美洲))、Roche (瑞士) 和 Sanofi (法国)。

Popular M&A news in 药店

• Clario 已收购 NRx Pharmaceuticals (公布2025三月18号).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (公布2025三月12号).
• Jazz Pharmaceuticals 已收购 Chimerix (公布2025三月6号).

药店 行业的其他推荐联系人

• Adare Pharmaceuticals 企业 Kristin Berkinsky - Chief Human Resources Officer
• Braeburn Pharmaceuticals 企业 Seth Harrison - Chairman and Director
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board

了解更多有关药店行业的信息 >

I-Mab Biopharma 的最新新闻稿

• I-Mab | I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
• I-Mab | I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
• I-Mab | News Releases
• I-Mab | I-Mab to Host 2022 R&D Day
• I-Mab | I-Mab Receives Top Rankings in Five Categories by Institutional Investor
• I-Mab | I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
• I-Mab | I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
• I-Mab | I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
• I-Mab | News Releases
• I-Mab | I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
• View more press releases Close

关于 I-Mab Biopharma 的社交媒体

• I-Mab Biopharma 在 维基百科、谷歌新闻 和 雅虎财经
• I-Mab Biopharma 在 LinkedIn、叽叽喳喳 和 YouTube